KAKaren Anthony

Karen Anthony

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Karen Anthony has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A unified model for Duchenne muscular dystrophy gene involvement in cancer: context‐dependent tumour suppression and oncogenicity

    by Lee Machado, Leanne Jones, Sonika Divakar, Michael Naidoo, Karen Anthony

    Evidence implicates the Duchenne muscular dystrophy gene ( DMD ) in tumorigenesis, but survival trends are inconsistent. To resolve this, we conducted a comprehensive global analysis of DMD expression and survival outcomes across 33 tumour types using bulk RNA sequencing data from The Cancer Genome Atlas. We examined the impact of total DMD , individual transcript and dystrophin‐associated protein complex (DAPC) gene expression levels on overall survival using Kaplan–Meier analysis, Cox proportional hazard modelling and pathway analysis. DMD expression was significantly associated with survival in nine cancers after Bonferroni correction (α = 0.0015), with high expression linked to either improved or worsened outcomes depending on cancer type. The most abundant DMD transcript, Dp71ab, mirrored total DMD trends, distinguishing two tumour groups with opposing survival associations. Hierarchical clustering suggests these divergent effects may be linked to a subset of signalling and adhesion‐related DAPC components. Our findings indicate that DMD does not act uniformly as an oncogene or tumour suppressor. Instead, we propose a context‐dependent dual model whereby high DMD expression is tumour suppressive in aggressive cancers and oncogenic in less aggressive tumours.


  • Open Access

    Duchenne muscular dystrophy gene product expression is associated with survival in head and neck squamous cell carcinoma

    by Leanne Jones, Sonika Divakar, Lewis Collins, Wael Hamarneh, Phillip Ameerally, Karen Anthony, Lee Machado

    Mutation of the Duchenne muscular dystrophy (DMD) gene causes neuromuscular disorders, but increasing evidence has implicated DMD in the development and progression of several major cancer types. This study investigates the prognostic and biological significance of DMD expression in head and neck squamous cell carcinoma (HNSCC). Analysis of The Cancer Genome Atlas (TCGA) data revealed that high DMD expression correlates with improved overall (median survival difference: 22 months, p = 0.0083) and progression-free (p = 0.0237) survival. The Dp71ab transcript is most strongly associated with better outcomes (median overall survival: 42 months, p = 0.0007). Notably, DMD expression levels stratify HPV-positive patients, identifying a DMD low/HPV-positive subgroup with poor outcomes. Immunohistochemical analysis of 50 HNSCC tissue cases confirmed dystrophin localisation in the nucleus and cytoplasm, with high nuclear expression linked to longer overall survival (mean difference: 31 months, p = 0.0497). Functional assays in HNSCC cells showed that Dp71ab overexpression disrupts nuclear morphology and reduces proliferation. Differential gene expression analysis additionally identified 388 upregulated and 30 downregulated genes, with pathways linked to muscle processes, ribosome biogenesis and non-coding RNA regulation. These findings highlight DMD as a potential biomarker and/or therapeutic target in HNSCC, warranting further mechanistic studies of Dp71 isoforms.


  • Open Access

    Duchenne muscular dystrophy gene expression is an independent prognostic marker for IDH mutant low-grade glioma

    by Michael Naidoo, Leanne Jones, Benjamin Conboy, Wael Hamarneh, Darwin D’sOuza, Karen Anthony, Lee R. Machado

    Alterations in the expression of the Duchenne muscular dystrophy (DMD) gene have been associated with the development, progression and survival outcomes of numerous cancers including tumours of the central nervous system. We undertook a detailed bioinformatic analysis of low-grade glioma (LGG) bulk RNAseq data to characterise the association between DMD expression and LGG survival outcomes. High DMD expression was significantly associated with poor survival in LGG with a difference in median overall survival between high and low DMD groups of over 7 years (P = < 0.0001). In a multivariate model, DMD expression remained significant (P = 0.02) and was an independent prognostic marker for LGG. The effect of DMD expression on overall survival was only apparent in isocitrate dehydrogenase (IDH) mutant cases where non-1p/19q co-deleted LGG patients could be further stratified into high/low DMD groups. Patients in the high DMD group had a median overall survival time almost halve that of the low DMD group. The expression of the individual DMD gene products Dp71, Dp71ab and Dp427m were also significantly associated with overall survival in LGG which have differential biological effects relevant to the pathogenesis of LGG. Differential gene expression and pathway analysis identifies dysregulated biological processes relating to ribosome biogenesis, synaptic signalling, neurodevelopment, morphogenesis and immune pathways. Genes spanning almost the entirety of chromosome 1p are upregulated in patients with high overall DMD, Dp71 and Dp427m expression which worsens survival outcomes for these patients. We confirmed dystrophin protein is variably expressed in LGG tumour tissue by immunohistochemistry and, overall, demonstrate that DMD expression has potential utility as an independent prognostic marker which can further stratify IDH mutant LGG to identify those at risk of poor survival. This knowledge may improve risk stratification and management of LGG.


  • Open Access

    A Survey of Machine Learning Approaches Applied to Gene Expression Analysis for Cancer Prediction

    by Mahmood Khalsan, Lee R. Machado, Eman Salih Al-Shamery, Suraj Ajit, Karen Anthony, Mu Mu, Michael Opoku Agyeman, Mahmood Jasim

    Machine learning approaches are powerful techniques commonly employed for developing cancer prediction models using associated gene expression and mutation data. Our survey provides a comprehensive review of recent cancer studies that have employed gene expression data from several cancer types (breast, lung, kidney, ovarian, liver, central nervous system and gallbladder) for survival prediction,tumor identification and stratification. We also provide an overview of biomarker studies that are associated with these cancer types. The survey captures multiple aspects of machine learning associated cancer studies,including cancer classification, cancer prediction, identification of biomarker genes, microarray, and RNA-Seq data.We discuss the technical issues with current cancer prediction models and the corresponding measurement tools for determining the activity levels of gene expression between cancerous tissues and noncancerous tissues. Additionally, we investigate how identifying putative biomarker gene expression patterns can aid in predicting future risk of cancer and inform the provision of personalized treatment.


  • Open Access

    RNA-based therapeutics for neurological diseases

    by Karen Anthony

    RNA-based therapeutics have entered the mainstream with seemingly limitless possibilities to treat all categories of neurological disease. Here, common RNA-based drug modalities such as antisense oligonucleotides, small interfering RNAs, RNA aptamers, RNA-based vaccines and mRNA drugs are reviewed highlighting their current and potential applications. Rapid progress has been made across rare genetic diseases and neurodegenerative disorders, but safe and effective delivery to the brain remains a significant challenge for many applications. The advent of individualized RNA-based therapies for ultra-rare diseases is discussed against the backdrop of the emergence of this field into more common conditions such as Alzheimer’s disease and ischaemic stroke. There remains significant untapped potential in the use of RNA-based therapeutics for behavioural disorders and tumours of the central nervous system; coupled with the accelerated development expected over the next decade, the true potential of RNA-based therapeutics to transform the therapeutic landscape in neurology remains to be uncovered.


  • Open Access

    The Duchenne muscular dystrophy gene and cancer

    by Leanne Jones, Michael Naidoo, Lee R. Machado, Karen Anthony

    Background: Mutation of the Duchenne muscular dystrophy (DMD)gene causes Duchenne and Becker muscular dystrophy, degenerative neuromuscular disorders that primarily affect voluntary muscles. However, increasing evidence implicatesDMDin the development of all major cancer types.DMDis a large gene with 79 exons that codes for the essential muscle protein dystrophin. Alternative promotor usage drives the production of several additional dystrophin protein products with roles that extend beyond skeletal muscle. The importance and function(s) of these gene products outside of muscle are not well understood.Conclusions: We highlight a clear role forDMDin the pathogenesis of several cancers, including sarcomas, leukaemia’s, lymphomas, nervous system tumours, melanomas and various carcinomas. We note that the normal balance ofDMDgene products is often disrupted in cancer. The short dystrophin protein Dp71 is, for example, typically maintained in cancer whilst the full-length Dp427 gene product, a likely tumour suppressor, is frequently inactivated in cancer due to a recurrent loss of 5’ exons. Therefore, the ratio of short and long gene products may be important in tumorigenesis. In this review, we summarise the tumours in whichDMDis implicated and provide a hypothesis for possible mechanisms of tumorigenesis, although the question of cause or effect may remain. We hope to stimulate further study into the potential role ofDMDgene products in cancer and the development of novel therapeutics that targetDMD.


  • Open Access

    Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy

    by Michael Naidoo, Karen Anthony

    Duchenne muscular dystrophy (DMD) is caused by frameshift mutations in theDMDgene that prevent the body-wide translation of its protein product, dystrophin. Besides a severe muscle phenotype, cognitive impairment and neuropsychiatric symptoms are prevalent. Dystrophin protein 71 (Dp71) is the majorDMDgene product expressed in the brain and mutations affecting its expression are associated with the DMD neuropsychiatric syndrome. As with dystrophin in muscle, Dp71 localises to dystrophin-associated protein complexes in the brain. However, unlike in skeletal muscle; in the brain, Dp71 is alternatively spliced to produce many isoforms with differential subcellular localisations and diverse cellular functions. These include neuronal differentiation, adhesion, cell division and excitatory synapse organisation as well as nuclear functions such as nuclear scaffolding and DNA repair. In this review, we first describe brain involvement in DMD and the abnormalities observed in the DMD brain. We then review the gene expression, RNA processing and functions of Dp71. We review genotype-phenotype correlations and discuss emerging cellular/tissue evidence for the involvement of Dp71 in the neuropathophysiology of DMD. The literature suggests changes observed in the DMD brain are neurodevelopmental in origin and that their risk and severity is associated with a cumulative loss of distalDMDgene products such as Dp71. The high risk of neuropsychiatric syndromes in Duchenne patients warrants early intervention to achieve the best possible quality of life. Unravelling the function and pathophysiological significance of dystrophin in the brain has become a high research priority to inform the development of brain-targeting treatments for Duchenne.


  • Open Access

    A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures

    by Monika Hiller, Maria Sofia Falzarano, Iker Garcia-Jimenez, Valentina Sardone, Ruurd C Verheul, Linda Popplewell, Karen Anthony, Estibaliz Ruiz-Del-Yerro, Hana Osman, Jelle J Goeman, et al.

    Duchenne muscular dystrophy is a lethal disease caused by lack of dystrophin. Skipping of exons adjacent to out-of-frame deletions has proven to restore dystrophin expression in Duchenne patients. Exon 51 has been the most studied target in both preclinical and clinical settings and the availability of standardized procedures to quantify exon skipping would be advantageous for the evaluation of preclinical and clinical data. To compare methods currently used to quantify antisense oligonucleotide–induced exon 51 skipping in the DMD transcript and to provide guidance about the method to use. Six laboratories shared blinded RNA samples from Duchenne patient-derived muscle cells treated with different amounts of exon 51 targeting antisense oligonucleotide. Exon 51 skipping levels were quantified using five different techniques: digital droplet PCR, single PCR assessed with Agilent bioanalyzer, nested PCR with agarose gel image analysis by either ImageJ or GeneTools software and quantitative real-time PCR. Differences in mean exon skipping levels and dispersion around the mean were observed across the different techniques. Results obtained by digital droplet PCR were reproducible and showed the smallest dispersion. Exon skipping quantification with the other methods showed overestimation of exon skipping or high data variation. Our results suggest that digital droplet PCR was the most precise and quantitative method. The quantification of exon 51 skipping by Agilent bioanalyzer after a single round of PCR was the second-best choice with a 2.3-fold overestimation of exon 51 skipping levels compared to digital droplet PCR.